Cancer drug trial halted after just one patient
NCT ID NCT05110781
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether the immunotherapy drug atezolizumab could shrink head and neck skin cancers that had spread to lymph nodes before surgery. Only 1 person enrolled before the study was terminated early. The goal was to see if the drug could eliminate all cancer cells in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab (immunotherapy drug)
- What this could lead to
- If it worked, this approach could help shrink head and neck skin cancers before surgery, potentially improving outcomes.
- What could go wrong
- The trial was terminated early with only 1 participant, so no reliable conclusions can be drawn. Immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- Could an antidepressant ease cancer treatment pain? new study investigates
- New study aims to make allergy testing safer for cancer patients on biologics
- Immunotherapy drug may save eyes from aggressive skin cancer
- New proton beam therapy aims to zap head and neck cancer with fewer side effects
- New drug aims to ease painful mouth sores for head and neck cancer patients